(Q61936398)
Statements
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH) (English)
0 references
April 2010
0 references
October 2011
0 references
414
0 references
45 year
0 references